Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
15.73
-0.36 (-2.24%)
At close: Mar 28, 2025, 4:00 PM
15.29
-0.44 (-2.80%)
Pre-market: Mar 31, 2025, 8:53 AM EDT
Arcutis Biotherapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Arcutis Biotherapeutics stock have an average target of 18.8, with a low estimate of 15 and a high estimate of 21. The average target predicts an increase of 19.52% from the current stock price of 15.73.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Arcutis Biotherapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 3 | 4 | 4 |
| Buy | 1 | 1 | 0 | 1 | 1 | 1 |
| Hold | 2 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 5 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Maintains $16 → $19 | Strong Buy | Maintains | $16 → $19 | +20.79% | Mar 11, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $13 → $15 | Hold | Maintains | $13 → $15 | -4.64% | Feb 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +20.79% | Feb 26, 2025 |
| Mizuho | Mizuho | Buy Maintains $20 → $21 | Buy | Maintains | $20 → $21 | +33.50% | Feb 26, 2025 |
| Needham | Needham | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +27.15% | Feb 26, 2025 |
Financial Forecast
Revenue This Year
307.79M
from 196.54M
Increased by 56.60%
Revenue Next Year
442.06M
from 307.79M
Increased by 43.62%
EPS This Year
-0.85
from -1.16
EPS Next Year
0.05
from -0.85
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 372.8M | 588.0M | 771.8M | ||
| Avg | 307.8M | 442.1M | 616.5M | ||
| Low | 276.8M | 333.1M | 335.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 89.7% | 91.0% | 74.6% | ||
| Avg | 56.6% | 43.6% | 39.5% | ||
| Low | 40.8% | 8.2% | -24.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.55 | 0.89 | 2.81 | ||
| Avg | -0.85 | 0.05 | 1.56 | ||
| Low | -1.11 | -0.44 | 0.54 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 5,141.9% | ||
| Avg | - | - | 2,807.1% | ||
| Low | - | - | 904.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.